All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

April 22nd 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.

Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC

April 21st 2024

Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

April 20th 2024

Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.

Avutometinib Plus Defactinib Makes a Phase 3 Debut in Low-Grade Serous Ovarian Cancer

April 19th 2024

Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

April 19th 2024

The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.

First-Line Pembrolizumab Plus Chemo Wins Canadian Approval for HER2– Advanced Gastric/GEJ Adenocarcinoma

April 19th 2024

Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.

Study Provides a First Look at Oncologists' Views on Ethical Implications of AI in Cancer Care

April 19th 2024

In a survey, over 200 oncologists agreed on how AI can be responsibly integrated into patient care and how to protect patients from hidden biases of AI.

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

April 19th 2024

R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.

Functional Precision Medicine Method Aids Treatment Decision-Making in R/R Pediatric Cancers

April 19th 2024

A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.

Y-90 Radioembolization Plus Pembrolizumab Generates Early Efficacy Signals in HCC

April 18th 2024

Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024

Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024

Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.

Fox Chase Cancer Center Opens First New Jersey Location in Voorhees

April 18th 2024

Fox Chase Cancer Center is proud to welcome patients to its newly opened office, which is located at 502 Centennial Boulevard in Voorhees, New Jersey.

Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC

April 18th 2024

Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive bladder cancer.

CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates

April 18th 2024

Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.

EMA Grants Orphan Drug Designation to Annamycin in AML

April 18th 2024

The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.

FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection

April 18th 2024

The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.